0000899243-23-012167.txt : 20230503 0000899243-23-012167.hdr.sgml : 20230503 20230503202819 ACCESSION NUMBER: 0000899243-23-012167 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230418 FILED AS OF DATE: 20230503 DATE AS OF CHANGE: 20230503 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cheng Andrew CENTRAL INDEX KEY: 0001778307 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-38944 FILM NUMBER: 23885995 MAIL ADDRESS: STREET 1: 170 HARBOR WAY, 3RD FLOOR STREET 2: C/O AKERO THERAPEUTICS, INC. CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Akero Therapeutics, Inc. CENTRAL INDEX KEY: 0001744659 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-487-6488 MAIL ADDRESS: STREET 1: 601 GATEWAY BOULEVARD, SUITE 350 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 4 1 doc4.xml FORM 4 SUBMISSION X0407 4 2023-04-18 0 0001744659 Akero Therapeutics, Inc. AKRO 0001778307 Cheng Andrew C/O AKERO THERAPEUTICS, INC. 601 GATEWAY BOULEVARD, SUITE 350 SOUTH SAN FRANCISCO CA 94080 1 1 0 0 President & CEO 1 Common Stock 2023-04-18 4 M 0 40000 0.615 A 409293 D Common Stock 2023-05-01 4 M 0 25000 0.615 A 434293 D Common Stock 2023-05-01 4 S 0 21523 45.0049 D 412770 D Common Stock 2023-05-01 4 S 0 3477 45.5045 D 409293 D Stock Option (Right to Buy) 0.615 2023-04-18 4 M 0 40000 0.00 D 2028-09-07 Common Stock 40000 157212 D Stock Option (Right to Buy) 0.615 2023-05-01 4 M 0 25000 0.00 D 2028-10-17 Common Stock 25000 85868 D The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.41 to $45.40, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.41 to $45.73, inclusive. The options are vested and currently exercisable. /s/ Jonathan Young, Attorney-in-Fact 2023-05-03